Search

Your search keyword '"Weiss, T. W."' showing total 4 results
Start Over Author "Weiss, T. W." Publication Year Range Last 10 years
4 results on '"Weiss, T. W."'

1. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study

Author

De Caterina, R., Kelly, P., Monteiro, P., Deharo, J. C., de Asmundis, C., López-de-Sá, E., Weiss, T. W., Waltenberger, J., Steffel, J., de Groot, J. R., Levy, P., Bakhai, A., Zierhut, W., Laeis, P., Reimitz, P. -E., Kirchhof, P., on behalf of the ETNA-AF-Europe investigators, Clinical sciences, Heartrhythmmanagement, Institute of Clinical Physiology, National Council of Research, NS Research, Novartis Institutes for BioMedical Research (NIBR), Division of Medicine, University College of London [London] (UCL), Neurovascular Clinical Science Unit, Catherine McAuley Centre, Mater Misericordiae University Hospital, Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Laboratoire d'Economie de Dauphine (LEDa), Université Paris Dauphine-PSL, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Laboratoire d'Economie et de Gestion des Organisations de Santé (Legos), Department of Medicine, Royal Free (DEPARTMENT OF MEDICINE, ROYAL FREE), Royal Free and University College London School of Medicine, Daiichi Sankyo Inc., Daiichi Sankyo Co., ACS - Heart failure & arrhythmias, Cardiology, University of Zurich, and De Caterina, Raffaele

Subjects
Research design, Time Factors, medicine.drug_mechanism_of_action, Pyridines, Administration, Oral, Major bleeding, 030204 cardiovascular system & hematology, chemistry.chemical_compound, 0302 clinical medicine, Edoxaban, Stroke prevention, Atrial Fibrillation, Epidemiology, Routine clinical practice, Prospective Studies, Registries, 030212 general & internal medicine, Prospective cohort study, Stroke, [QFIN]Quantitative Finance [q-fin], Atrial fibrillation, General Medicine, 3. Good health, Europe, JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I11 - Analysis of Health Care Markets, Treatment Outcome, ETNA-AF-Europe study, Research Design, 10209 Clinic for Cardiology, epidemiology, Cardiology and Cardiovascular Medicine, Registry, medicine.medical_specialty, Factor Xa Inhibitor, 610 Medicine & health, Hemorrhage, 2705 Cardiology and Cardiovascular Medicine, 03 medical and health sciences, Nonvitamin K antagonist oral anticoagulants, Internal medicine, medicine, Humans, cardiovascular diseases, Safety outcomes, business.industry, PREFER in AF, medicine.disease, JEL: I - Health, Education, and Welfare/I.I1 - Health/I.I1.I12 - Health Behavior, Thiazoles, Real-world, chemistry, business, Factor Xa Inhibitors
Abstract

AIM: Edoxaban, a nonvitamin K antagonist oral anticoagulant, is an oral factor Xa inhibitor approved for the prevention of stroke and systemic embolism in adult patients with atrial fibrillation and for the treatment and secondary prevention in adult patients with venous thromboembolism (VTE). This study details the design of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study - a postauthorization observational study, which is part of the postapproval plan for edoxaban agreed with the European Medicines Agency. METHODS: The ETNA-AF-Europe study (Clinicaltrials.gov: NCT02944019) is a multicenter, prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated with edoxaban from 852 sites across 10 European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland, and the United Kingdom). Patients treated with edoxaban were prospectively enrolled and will be followed up for 4 years with yearly follow-up visits. ASSESSMENTS: The primary objective of the ETNA-AF-Europe study is to assess the real-world safety of edoxaban by evaluating bleeding events, including intracranial hemorrhage; drug-related adverse events, such as hepatic events; and cardiovascular and all-cause mortality. In addition, efficacy will be assessed by recording major adverse cardiovascular events including stroke, systemic embolic events, transient ischemic attacks, and also VTE episodes, acute coronary syndromes, and hospitalizations related to cardiovascular condition. Event rates will be compared with event rates reported in the PREvention oF thromboembolic events-European Registry in Atrial Fibrillation in atrial fibrillation (PREFER in AF) and PREFER in AF Prolongation registries, and in the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48 study datasets.

Published
2019
Full Text
View/download PDF

2. P4756Stroke and bleeding in low, intermediate and high risk patients with atrial fibrillation treated with edoxaban: Results of the ETNA-AF Europe registry

Author

De Groot, J R, primary, De Caterina, R, additional, Kelly, P, additional, Monteiro, P, additional, Deharo, J C, additional, De Asmundis, C, additional, Lopez De Sa, E, additional, Weiss, T W, additional, Waltenberger, J, additional, Steffel, J, additional, Levy, P, additional, Bakhai, A, additional, and Kirchhof, P, additional

Published
2019
Full Text
View/download PDF

4. Safety and efficacy of pharmacological cardioversion of recent-onset atrial fibrillation: a single-center experience.

Author

Kriz R, Freynhofer MK, Weiss TW, Egger F, Gruber SC, Eisenburger P, Wojta J, Huber K, and Koch J

Subjects
Aged, Atrial Fibrillation physiopathology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation drug therapy, Electrocardiography
Abstract

Background and Aim: The management of patients with recent-onset atrial fibrillation (AF) presenting at emergency departments (EDs) varies widely. Our aim was to describe the management of patients with recent-onset (<48 hours) AF, to determine safety and efficacy of pharmacological cardioversion at the ED, and to evaluate the incidence of thromboembolism or death at 30 days., Methods: In a prospective, observational, single-center study, 236 subjects with recent-onset AF were consecutively enrolled from January 2011 until January 2013. Follow-up information was obtained by reviewing all available clinical records., Results: As first-line therapy, 45.3% (n = 107) received ibutilide, 28.8% (n = 68) vernakalant, 25% (n = 59) flecainide, and 0.8% (n = 2) amiodarone, respectively. Successful cardioversion was achieved in 72.5% (n = 171) of patients after first-line therapy. There was no significant difference between treatment groups. In univariable logistic regression analysis, age (odds ratio [OR] = 1.027; 95% confidence interval [CI], 1.003-1.052; P= .03), duration of symptoms (OR = 0.968; 95% CI, 0.938-0.999; P= .045), as well as the CHA2DS2-VASc score (1 point for Congestive heart failure, Hypertension, Age between 65 and 74 years, Diabetes, Vascular disease, Sex category if female and 2 points for previous TIA/Stroke and Age ≥ 75 years) (OR = 1.237; 95% CI, 1.01-1.515; P= .04) were associated with success of pharmacological cardioversion. Within 30 days, 1 patient suffered from fatal ischemic stroke., Conclusion: Pharmacological cardioversion followed by discharge after a short observation period is safe. There was no significant difference between the agents used in terms of short-term safety and efficacy. Importantly, the coherence of the ED to recent guidelines regarding first-line therapy is high., (Copyright © 2016 Elsevier Inc. All rights reserved.)

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results